Drug Profile


Alternative Names: Cetrorelix acetate; Cetrorelix pamoate; Cetrotide; NS 75A; NS 75B; SB 075; SB 75

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Tulane University
  • Developer AEterna Zentaris Inc; Merck Serono; Shionogi
  • Class Infertility therapies; Peptides
  • Mechanism of Action Gonadotropin releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Female infertility
  • Discontinued Benign prostatic hyperplasia; Breast cancer; Endometriosis; Ovarian cancer; Prostate cancer; Uterine leiomyoma

Most Recent Events

  • 01 Oct 2013 AEterna Zentaris completes transfer of worldwide manufacturing rights to cetrorelix to Merck KGaA (Merck Serono)
  • 01 Jul 2013 Handok Pharmaceuticals is now called Handok Inc
  • 23 Apr 2013 AEterna Zentaris announces its decision to transfer manufacturing rights to cetrorelix to Merck KGaA (Merck Serono)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top